Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.
The closing price of Cardiff Oncology Inc (NASDAQ: CRDF) was $3.94 for the day, up 7.95% from the previous closing price of $3.65. In other words, the price has increased by $7.95 from its previous closing price. On the day, 2.12 million shares were traded. CRDF stock price reached its highest trading level at $4.09 during the session, while it also had its lowest trading level at $3.71.
Ratios:
Our analysis of CRDF’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 6.22 and its Current Ratio is at 6.22. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Ladenburg Thalmann on July 08, 2025, initiated with a Buy rating and assigned the stock a target price of $19.
On June 24, 2025, Jefferies started tracking the stock assigning a Hold rating and target price of $3.50.
On September 06, 2024, Craig Hallum started tracking the stock assigning a Buy rating and target price of $8.Craig Hallum initiated its Buy rating on September 06, 2024, with a $8 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Dec 17 ’24 when Levine James E. bought 2,752 shares for $5.42 per share. The transaction valued at 14,905 led to the insider holds 65,316 shares of the business.
Levine James E. bought 2,400 shares of CRDF for $12,000 on Dec 18 ’24. The Chief Financial Officer now owns 67,716 shares after completing the transaction at $5.00 per share. On Dec 16 ’24, another insider, Levine James E., who serves as the Chief Financial Officer of the company, bought 2,564 shares for $3.83 each. As a result, the insider paid 9,820 and bolstered with 62,564 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CRDF now has a Market Capitalization of 262112048 and an Enterprise Value of 131025440. For the stock, the TTM Price-to-Sale (P/S) ratio is 444.25 while its Price-to-Book (P/B) ratio in mrq is 3.70. Its current Enterprise Value per Revenue stands at 223.212 whereas that against EBITDA is -2.534.
Stock Price History:
The Beta on a monthly basis for CRDF is 1.56, which has changed by 0.78280544 over the last 52 weeks, in comparison to a change of 0.10500872 over the same period for the S&P500. Over the past 52 weeks, CRDF has reached a high of $5.64, while it has fallen to a 52-week low of $2.01. The 50-Day Moving Average of the stock is 23.14%, while the 200-Day Moving Average is calculated to be 17.88%.
Shares Statistics:
CRDF traded an average of 1.21M shares per day over the past three months and 1524120 shares per day over the past ten days. A total of 66.53M shares are outstanding, with a floating share count of 60.75M. Insiders hold about 8.68% of the company’s shares, while institutions hold 42.24% stake in the company. Shares short for CRDF as of 1749772800 were 17289872 with a Short Ratio of 14.28, compared to 1747267200 on 17522454. Therefore, it implies a Short% of Shares Outstanding of 17289872 and a Short% of Float of 26.680002.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
